Your session is about to expire
← Back to Search
EFX 50 mg for Nonalcoholic Steatohepatitis or Metabolic Steatohepatitis
Study Summary
This trial tests a new drug, EFX, to see if it can help treat NASH, NAFLD, and related conditions. It's a randomized, double-blind study with placebo control.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who is eligible to take part in this clinical experiment?
"The medical trial is looking for 600 individuals with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH) that are aged between 18 and 80."
Does this research initiative require more study participants?
"Affirmative. Information on clinicaltrials.gov suggests that this medical experiment, first announced in November of 2023, is actively recruiting participants. The study requires 600 individuals to be recruited from 46 different locations."
Has the FDA sanctioned EFX 50 mg for medicinal use?
"Our team's determination of EFX 50 mg being a 3 on the safety scale is based off its Phase 3 trial status, which shows evidence of not only efficacy but also multiple rounds verifying its security."
What is the maximal capacity of individuals taking part in this scientific experiment?
"Affirmative. The records posted on clinicaltrials.gov verify that this research is currently enrolling participants and the original posting date was November 9th 2023, with a recent update of November 29th 2023. 600 individuals will be accepted from 46 sites nation-wide."
Is the participant pool for this research restricted to adults aged 25 and over?
"The trial is seeking individuals aged 18 and up, but not exceeding 80 years of age."
Are there several sites in the US currently running this research project?
"Currently, potential participants can register for this trial from 46 distinct sites. These include cities such as Los Angeles, Conway and Viera; to reduce travel requirements it is prudent to identify the closest clinic."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Tandem Clinical Research, New York: < 48 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger